Pharmacological characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation
preprint
OA: closed
AI-generated summary
This study characterized the pharmacokinetics of FC-12738, a novel retro-inverso pentapeptide for neuroinflammation, in rats and dogs, finding favorable properties but noting potential need for CNS penetrance improvement.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
FC-12738, a retro-inverso pentapeptide developed by Neurodegenerative Disease Research, Inc., is currently under investigation for treating neuroinflammation associated with amyotrophic lateral sclerosis (ALS). This study aimed to evaluate the pharmacokinetic properties of FC-12738, including absorption, distribution, metabolism, excretion, and drug-drug interactions. Pharmacokinetics were assessed in Sprague-Dawley rats and beagle dogs following intravenous and subcutaneous administration. Our findings suggest that FC-12738 demonstrates many favorable pharmacokinetic properties, although further optimization may be required to improve CNS penetrance.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00